mRNA vaccine technology has expanded beyond COVID-19. Key 2026 developments: (1) RSV: Moderna mRNA-1345 achieved 83% efficacy against severe RSV in Phase III, F…
GLP-1 receptor agonists (semaglutide, tirzepatide) have transformed obesity treatment with 15-22% average weight loss in clinical trials. New research in 2026 s…